Modified T cells are developed by genetically modifying patient’s own T cells to present the selected transduced T cell receptors (TCR) and then re-infusing the T cells into the patient.
Life Technologies chairman and chief executive officer Gregory Lucier said the partnership with Adaptimmune demonstrates the company’s commitment to deliver technologies that integrate the delivery of next generation therapies currently under development to treat the most critically ill patients.
"Life Technologies believes in the promise of cellular and genomic medicine and is dedicated to nurturing innovation in this emerging therapeutic field," Lucier added.
Financial details of the licensing agreement have not been disclosed.
Adaptimmune chief executive officer James Noble said the deal takes the company to the next stage by securing a long-term and exclusive route to manufacturing its products for late-stage clinical studies and, if those trials are successful, for the market.
"Adaptimmune can now not only create TCRs for T cell therapy, but also exclusively use the intellectual property needed for the manufacturing process and commercialization," Noble added.